查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405862

美國獸醫整形外科市場規模、佔有率、趨勢分析報告：按產品類型、動物類型、應用、給藥途徑、最終用途、細分市場預測，2024-2030 年

U.S. Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Viscosupplements, Pharmaceuticals), By Animal Type, By Application, By Route Of Administration, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國獸醫整形外科市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2024年至2030年美國獸用整形外科藥品市場規模將以7.2%的複合年成長率成長，到2030年將達到8.1451億美元。

這個市場主要是由寵物數量的成長、寵物保險的引入、動物疾病盛行率的上升以及獸醫學的進步所推動的。

例如，2023年10月，FDA核准了Librela（bedinvetmab注射液），這是第一個治療犬類骨關節炎相關疼痛的單株抗體。此外，2022 年 4 月，American Regent, Inc. 的子公司 American Regent Animal Health 獲得 FDA核准，可延長 Adequan Canine 和 Adequan im 的保存期限。

為了增加在市場上的影響力，獸醫整形外科市場的主要企業正在採取產品發布、聯盟和收購等策略性舉措，從而推動市場成長。 2022年9月，碩騰收購了Jurox，這是一家專門生產牲畜和伴同性動物動物用藥品的私人公司。此次收購於 2021 年 8 月完成，收購範圍包括 Jurox 的澳洲業務以及美國、加拿大和英國的區域辦事處。這些舉措預計將推動市場成長。

例如，2023 年 10 月，細胞治療和再生醫學公司 Athersys, Inc. (ATHX) 與 Ardent Animal Health 簽訂了許可協議。透過這項舉措，以重症加護的多幹細胞 (invimestrocell) 研究而聞名的 Athersys 進入了動物健康領域。與專注於動物再生醫學和癌症治療的獸醫生物技術公司 Ardent 的合作突顯了 Athersys 對推動動物醫學的承諾。

疫情和相關封鎖對市場的主要影響包括成長放緩、銷售下降、供應鏈中斷和營運挑戰。然而，疫情增加了人們對動物健康和福利的興趣，加強了寵物父母與動物之間的聯繫，並增加了寵物的擁有量。此外，市場醫療率、寵物支出和寵物保險採用率也有所改善。

COVID-19 大流行對獸醫部門的其他正面影響包括寵物人性化程度的提高和診斷率的提高。 2021年，市場對動物用藥品（包括整形外科藥品）的需求和銷售均出現成長。 2022年，全球經濟景氣衰退、成本通膨等宏觀經濟不確定性對我們的業務產生了負面影響。然而，由於狗和馬的整形外科疾病日益流行，由於潛在的市場促進因素保持不變，預計市場在估計和預測期內將出現顯著成長。

美國獸醫整形外科市場報告亮點

  • 從產品來看，預計到 2023 年，製藥業將佔據市場主導地位，佔有率為 46.72%。針對寵物整形外科疾病的藥物治療，例如非類固醇消炎劑(NSAID) 和止痛藥物，被廣泛使用並確立為控制疼痛和發炎的有效治療方法。另一方面，粘膠補充品領域預計在預測期內將以 8.23% 的複合年成長率成長最快。
  • 根據動物類型，市場分為狗和馬。狗類細分市場佔據主導地位，2023 年佔 51.98% 的佔有率。預計未來 10 年複合年成長率將達到 7.80%。
  • 從應用來看，骨關節炎領域中佔最大，2023年將達60.65%。其他細分市場預計在預測期內將以 9.39% 的最快複合年成長率成長。
  • 根據給藥途徑，市場分為注射劑、口服劑和其他劑型（例如外用劑）。注射劑佔據市場主導地位，2023 年佔有率為 60.40%。其他（主題等）細分市場預計未來 10 年將以 8.22% 的最快複合年成長率成長。
  • 依最終用途分類，獸醫院和診所部門在 2023 年佔據最大市場佔有率，達到 53.59%。預計其他細分市場在預測期內將以 8.68% 的複合年成長率成長最快。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國獸用整形外科藥品市場產業展望

  • 市場體系展望
  • 美國獸醫整形外科市場動態
  • 市場促進因素影響分析
  • 市場抑制因素影響分析
  • 市場機會分析
  • 市場問題分析
  • 美國獸醫整形外科市場：波特五力分析
  • 美國獸醫整形外科市場：PESTEL 分析
  • 寵物飼主人口統計與行為分析
  • COVID-19 大流行、經濟衰退和通貨膨脹的影響
  • 2018-2030年美國寵物狗和馬的估計數量（百萬隻）
  • 2022 年接受關節內注射的狗關節估計數量

第 4 章 2018-2030 年產品估算/趨勢分析

  • 美國獸醫整形外科市場（按產品）：要點
  • 2022年及2030年產品變化分析及市場佔有率
  • 依產品
    • 按生技藥品
    • 透過藥物
  • 生技藥品
    • 2018-2030 年生技藥品市場估計與預測
    • 幹細胞
    • 富含血小板血漿 (Prp)
    • 其他
  • 黏性補充品
    • 2018-2030 年 Visco補充品市場估計與預測
  • 藥品
    • 2018-2030 年醫藥市場估計與預測
    • 類固醇
    • 邊
    • 其他

第5章 2018-2030年應用預估及趨勢分析

  • 美國獸醫整形外科市場（按解決方案）：要點
  • 2022年和2030年應用變化分析和市場佔有率
  • 按用途
  • 骨關節炎（Oa）
    • 2018-2030 年骨關節炎市場估計與預測
    • 退化性關節疾病
    • 其他

第6章 2018-2030年給藥途徑估算及趨勢分析

  • 按給藥途徑的美國獸醫整形外科市場：要點
  • 2022年及2030年給藥途徑變化分析及市場佔有率
  • 依給藥途徑
    • 透過注射
  • 可注射的
    • 2018-2030 年注射劑市場估計與預測
    • 肌肉注射
    • 2018-2030年肌肉注射市場估計與預測
    • 關節內的
    • 2018-2030 年關節內市場估計與預測
    • 其他
    • 2018-2030 年其他市場估計與預測
  • 口服
    • 2018-2030 年口腔市場估計與預測
  • 其他
    • 2018-2030 年其他市場估計與預測

第7章 2018-2030年動物種類估算及趨勢分析

  • 按動物類型分類的美國獸醫整形外科市場：要點
  • 2022年和2030年狗的波動分析和市場佔有率
  • 依動物類型
    • 透過狗
  • 狗
    • 2018-2030 年狗市場估計與預測
    • 小型犬品種
    • 中型犬種
    • 大型犬種
  • 馬
    • 2018-2030 年馬匹市場估計與預測

第 8 章 2018-2030 年最終用途估計與趨勢分析

  • 美國獸醫整形外科市場（按最終用途）：要點
  • 2022 年和 2030 年最終用途變化分析和市場佔有率
  • 按最終用途
  • 獸醫醫院和診所
    • 2018-2030 年獸醫院和診所的市場估計和預測
  • 在家裡
    • 2018-2030 年家用市場估計與預測
  • 其他
    • 2018-2030 年其他市場估計與預測

第9章競爭形勢

  • 市場參與企業分類
  • 企業市場分析/堆圖分析
  • 策略規劃
    • 併購
    • 夥伴關係與協作
    • 其他
  • 公司簡介
    • Zoetis
    • Ardent Animal Health, LLC
    • Enso Discoveries
    • Arthrex, Inc.
    • VetStem, Inc.
    • Contura Vet US
    • MEDREGO LLC
    • PetVivo Holdings, Inc.（Spryng）
    • T-Cyte Therepeutics
    • Boehringer Ingelheim Animal Health USA Inc.
    • American Regent, Inc.
    • Bimeda US
    • Nucleus ProVets

第10章 要點

Product Code: GVR-4-68040-168-1

U.S. Veterinary Orthopedic Medicine Market Growth & Trends:

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys' commitment to advancing veterinary care.

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

U.S. Veterinary Orthopedic Medicine Market Report Highlights:

  • Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period
  • Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade
  • Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period
  • Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade
  • On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Regional Scope
    • 1.1.2 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information/data Analysis
    • 1.4.1 Information Analysis
  • 1.5 Market Formulation & Visualization
  • 1.6 Data Validation & Publishing
  • 1.7 Model Details
    • 1.7.1 Approach 1: Commodity Flow Analysis
      • 1.7.1.1 Hybrid Market Estimation Model
    • 1.7.2 Global Market: Cagr Calculation
    • 1.7.3 Approach 2: Parent Market Analysis
  • 1.8 List Of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 U.S. Veterinary Orthopedic Medicine Market Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Analysis
  • 3.2 U.S. Veterinary Orthopedic Medicine Market Dynamics
  • 3.3 Market Driver Impact Analysis
    • 3.3.1 Increasing Incidence Of Orthopedic Problems
    • 3.3.2 Growing Uptake Of Pet Insurance
    • 3.3.3 Increase In Canine & Equine Population
    • 3.3.4 Advancements In Veterinary Orthopedic Medicine
    • 3.3.5 Supportive Initiatives
  • 3.4 Market Restraint Impact Analysis
    • 3.4.1. High Cost Of Treatment
  • 3.5 Market Opportunity Analysis
  • 3.6 Market Challenge Analysis
  • 3.7 U.S. Veterinary Orthopedic Medicine Market: Porter's 5 Forces Analysis
    • 3.7.1 Bargaining Power Of Buyers: High
    • 3.7.2 Bargaining Power Of Suppliers: Moderate - Low
    • 3.7.3 Threat Of New Entrants: High
    • 3.7.4 Threat Of Substitutes: Low - Moderate
    • 3.7.5 Competitive Rivalry: High
  • 3.8 U.S. Veterinary Orthopedic Medicine Market: Pestel Analysis
    • 3.8.1 Political
    • 3.8.2 Economic
    • 3.8.3 Social
    • 3.8.4 Technological
    • 3.8.5 Environmental
    • 3.8.6 Legal
  • 3.9 Pet Owner Demographics & Behavior Analysis
  • 3.10 Impact Of Covid-19 Pandemic, Recession & Inflation
  • 3.11 U.S. Estimated Pet Dog & Horse Population (Million), 2018 To 2030
  • 3.12 Estimated Number Of Intra-articularly Injected Canine Joints, 2022

Chapter 4 Product Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 4.1 U.S. Veterinary Orthopedic Medicine Market By Product: Key Takeaways
  • 4.2 Product Movement Analysis & Market Share, 2022 & 2030
  • 4.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Product (USD Million)
    • 4.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Biologics (USD Million)
    • 4.3.2 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Pharmaceuticals (USD Million)
  • 4.4 Biologics
    • 4.4.1 Biologics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2 Stem Cells
      • 4.4.2.1 Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3 Platelet-rich Plasma (Prp)
      • 4.4.3.1 Platelet-rich Plasma (Prp) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4 Other Biologics
      • 4.4.4.1 Other Biologics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.5 Viscosupplements
    • 4.5.1 Viscosupplements Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.6 Pharmaceuticals
    • 4.6.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2 Steroids
      • 4.6.2.1 Steroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3 Nsaids
      • 4.6.3.1 Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4 Others
      • 4.6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Application Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 5.1 U.S. Veterinary Orthopedic Medicine Market By Solutions: Key Takeaways
  • 5.2 Application Movement Analysis & Market Share, 2022 & 2030
  • 5.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Application (USD Million)
  • 5.4 Osteoarthritis (Oa)
    • 5.4.1 Osteoarthritis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2 Degenerative Joint Disease
      • 5.4.2.1 Degenerative Joint Disease Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3 Others
      • 5.4.3.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Route Of Administration Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 6.1 U.S. Veterinary Orthopedic Medicine Market By Route Of Administration: Key Takeaways
  • 6.2 Route Of Administration Movement Analysis & Market Share, 2022 & 2030
  • 6.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Route Of Administration (USD Million)
    • 6.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Injectable (USD Million)
  • 6.4 Injectable
    • 6.4.1 Injectable Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2 Intra-muscular
    • 6.4.3 Intra-muscular Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4 Intra-articular
    • 6.4.5 Intra-articular Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6 Others
    • 6.4.7 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5 Oral
    • 6.5.1 Oral Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Animal Type Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 7.1 U.S. Veterinary Orthopedic Medicine Market, By Animal Type: Key Takeaways
  • 7.2 Dogs Movement Analysis & Market Share, 2022 & 2030
  • 7.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Animal Type (USD Million)
    • 7.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Dogs (USD Million)
  • 7.4 Dogs
    • 7.4.1 Dogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Small Breeds
      • 7.4.2.1 Small Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Medium-sized Breeds
      • 7.4.3.1 Medium-sized Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Large Breeds
      • 7.4.4.1 Large Breeds Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Horses
    • 7.5.1 Horses Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 End-use Estimates & Trend Analysis, 2018 - 2030 (USD Million)

  • 8.1 U.S. Veterinary Orthopedic Medicine Market By End-use: Key Takeaways
  • 8.2 End-use Movement Analysis & Market Share, 2022 & 2030
  • 8.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts By End-use (USD Million)
  • 8.4 Veterinary Hospitals & Clinics
    • 8.4.1 Veterinary Hospitals & Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5 At-home
    • 8.5.1 At-home Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6 Others
    • 8.6.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Strategy Mapping
    • 9.3.1. Mergers & Acquisitions
    • 9.3.2. Partnerships & Collaborations
    • 9.3.3. Others
  • 9.4. Company Profiles
    • 9.4.1. Zoetis
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Ardent Animal Health, LLC
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Enso Discoveries
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Arthrex, Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. VetStem, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Contura Vet US
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. MEDREGO LLC
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. PetVivo Holdings, Inc. (Spryng)
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. T-Cyte Therepeutics
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Boehringer Ingelheim Animal Health USA Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. American Regent, Inc.
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. Bimeda U.S.
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Strategic Initiatives
    • 9.4.13. Nucleus ProVets
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Strategic Initiatives

Chapter 10. Key Takeaways

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Impact of COVID-19, recession, & inflation on some key players
  • Table 3 U.S. veterinary orthopedic medicine market estimates and forecast, by product, 2018 - 2030 (USD million)
  • Table 4 U.S. veterinary orthopedic medicine market estimates and forecast, by Biologics, 2018 - 2030 (USD million)
  • Table 5 U.S. veterinary orthopedic medicine market estimates and forecast, by Pharmaceuticals, 2018 - 2030 (USD million)
  • Table 6 U.S. veterinary orthopedic medicine market estimates and forecast, by application, 2018 - 2030 (USD million)
  • Table 7 U.S. veterinary orthopedic medicine market estimates and forecast, by route of administration, 2018 - 2030 (USD million)
  • Table 8 U.S. veterinary orthopedic medicine market estimates and forecast, by injectable, 2018 - 2030 (USD million)
  • Table 9 U.S. veterinary orthopedic medicine market estimates and forecast, by animal type, 2018 - 2030 (USD million)
  • Table 10 U.S. veterinary orthopedic medicine market estimates and forecast, by dogs, 2018 - 2030 (USD million)
  • Table 11 U.S. veterinary orthopedic medicine market estimates and forecast, by end-use, 2018 - 2030 (USD million)
  • Table 12 Participants' overview
  • Table 13 Financial performance
  • Table 14 Products benchmarking
  • Table 15 Key companies undertaking acquisitions.
  • Table 16 Key companies launching new products.
  • Table 17 Key companies undertaking partnership & collaboration strategies.
  • Table 18 Key market players initiating expansion.

List of Figures

  • Fig. 1 U.S. Veterinary Orthopedic Medicine Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation and Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for commodity flow analysis of animal health market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent Market Analysis, 2023 (USD million)
  • Fig. 16 Ancillary market outlook, 2023
  • Fig. 17 U.S. Veterinary Orthopedic Medicine Market Dynamics
  • Fig. 18 U.S. Veterinary Orthopedic Medicine Market: PORTER's analysis
  • Fig. 19 U.S. Veterinary Orthopedic Medicine Market: PESTEL analysis
  • Fig. 20 U.S. Veterinary Orthopedic Medicine Market by product: Key takeaways
  • Fig. 21 U.S. Veterinary Orthopedic Medicine Market by Product, Market share, 2023 & 2030
  • Fig. 22 Biologics market, 2018 - 2030 (USD million)
  • Fig. 23 Stem cells market, 2018 - 2030 (USD million)
  • Fig. 24 PRP market, 2018 - 2030 (USD million)
  • Fig. 25 Other biologics market, 2018 - 2030 (USD million)
  • Fig. 26 Viscosupplements market, 2018 - 2030 (USD million)
  • Fig. 27 Pharmaceuticals market, 2018 - 2030 (USD million)
  • Fig. 28 Steroids market, 2018 - 2030 (USD million)
  • Fig. 29 NSAIDS market, 2018 - 2030 (USD million)
  • Fig. 30 Others market, 2018 - 2030 (USD million)
  • Fig. 31 U.S. veterinary orthopedic medicine market by application: Key Takeaways
  • Fig. 32 U.S. veterinary orthopedic medicine market by application, market share, 2023 & 2030
  • Fig. 33 Osteoarthritis market, 2018 - 2030 (USD million)
  • Fig. 34 Degenerative joint disease market, 2018 - 2030 (USD million)
  • Fig. 35 Platelet-Rich Plasma (PRP) market, 2018 - 2030 (USD million)
  • Fig. 36 U.S. veterinary orthopedic medicine market by route of administration: Key Takeaways
  • Fig. 37 U.S. veterinary orthopedic medicine market by route of administration, market share, 2023 & 2030
  • Fig. 38 Injectable market, 2018 - 2030 (USD million)
  • Fig. 39 Intra-Muscular market, 2018 - 2030 (USD million)
  • Fig. 40 Intra-Articular market, 2018 - 2030 (USD million)
  • Fig. 41 Others market, 2018 - 2030 (USD million)
  • Fig. 42 Oral market, 2018 - 2030 (USD million)
  • Fig. 43 Others market, 2018 - 2030 (USD million)
  • Fig. 44 U.S. veterinary orthopedic medicine market, by animal type: Key takeaways
  • Fig. 45 U.S. veterinary orthopedic medicine market, by animal type: Market share, 2023 & 2030
  • Fig. 46 Dogs market, 2018 - 2030 (USD million)
  • Fig. 47 Small breeds market, 2018 - 2030 (USD million)
  • Fig. 48 Medium-sized breeds market, 2018 - 2030 (USD million)
  • Fig. 49 Large breeds market, 2018 - 2030 (USD million)
  • Fig. 50 Horses market, 2018 - 2030 (USD million)
  • Fig. 51 U.S. veterinary orthopedic medicine market, by end-use: Key takeaways
  • Fig. 52 U.S. veterinary orthopedic medicine market, by end-use, market share, 2023 & 2030
  • Fig. 53 Veterinary hospitals & clinics market, 2018 - 2030 (USD million)
  • Fig. 54 At-home market, 2018 - 2030 (USD million)
  • Fig. 55 Others market, 2018 - 2030 (USD million)
  • Fig. 56 Market Participant categorization
  • Fig. 57 Strategic Framework